Table 2 Subgroup analyses of tumor take rate against duration of incubation, number of cells, injection volume, cell line and WHO grade for the five model groups
From: Meningioma animal models: a systematic review and meta-analysis
Subgroups | ECLM orthotopic TTR (95% CI) | ECLM heterotopic TTR (95% CI) | PTM orthotopic TTR (95% CI) | PTM heterotopic TTR (95% CI) | GEM TTR (95% CI) |
|---|---|---|---|---|---|
Duration of incubation | |||||
 0–14 days | 97% (92–99%) | 97% (93–99%) | NA | NA | NA |
 14–30 days | 93% (85–97%) | 94% (90–97%) | 98% (89–100%) | 94% (88–97%) | NA |
 31–99 days | 100% (91–100%) | 96% (93–98%) | 87% (65–96%) | 91% (80–96%) | 46% (5–93%) |
 100–199 days | 92% (70–98%) | 100% (54–100%) | NA | 75% (45–92%) | 36% (20–56%) |
 200–499 days | NA | NA | 8% (3%-21%) | 65% (37–86%) | 27% (20–35%) |
 Unknown | 95% (92–97%) | 97% (89–99%) | 67% (29–91%) | 34% (13–63%) | 38% (20–60%) |
Number of cells | |||||
 0–100 | NA | NA | 0% (0–46%) | NA | NA |
 101–1.000 | NA | NA | 86% (42–100%) | NA | NA |
 1.001–10.000 | NA | NA | 67% (22–96%) | 50% (12–88%) | NA |
 10.001–100.000 | 97% (93–99%) | 98% (91–100%) | 15% (5–37%) | 32% (3–88%) | NA |
 100.001–500.000 | 97% (94–99%) | 97% (92–99%) | NA | NA | NA |
 500.001–1.000.000 | 96% (91–99%) | 94% (85–97%) | 91% (77–97%) | 93% (49–99%) | NA |
 1.000.001–10.000.000 | 100% (48–100%) | 97% (95–99%) | NA | 94% (81–98%) | NA |
 > 10.000.000 | NA | 100% (66–100%) | NA | 96% (86–99%) | NA |
 Unknown | 89% (82–94%) | 93% (83–97%) | NA | 83% (73–90%) | NA |
Injection volume (μl) | |||||
 0–1 | 91% (56–99%) | NA | NA | NA | NA |
 2–5 | 95% (93–97%) | NA | 16% (5–40%) | NA | NA |
 6–10 | 98% (94–99%) | NA | 86% (69–94%) | NA | NA |
 0–99 | NA | 100% (96–100%) | NA | 97% (87–99%) | NA |
 100–250 | NA | 96% (93–98%) | NA | 94% (69–99%) | NA |
 251–500 | NA | 95% (79–99%) | NA | 88% (40–99%) | NA |
 501–1000 | NA | NA | NA | 76% (52–90%) | NA |
 Unknown | 92% (82–97%) | 96% (92–98%) | NA | 83% (73–90%) | NA |
Cell line | |||||
 IOMM-Lee | 97% (95–98%) | 94% (90–96%) | NA | NA | NA |
 CH-157 | 89% (81–94%) | 97% (89–99%) | NA | NA | NA |
 BEN-MEN-1 | 97% (81–100%) | NA | NA | NA | NA |
 HBL52 | NA | 99% (93–100%) | NA | NA | NA |
 HKBMM | 100% (86–100%) | 93% (77–98%) | NA | NA | NA |
 SF4433 | NA | 98% (85–100%) | NA | NA | NA |
 SF3061 | NA | 100% (88–100%) | NA | NA | NA |
 F5 | 95% (79–99%) | 100% (88–100%) | NA | NA | NA |
 KT21 | 95% (80–99%) | 100% (29–100%) | NA | NA | NA |
 NCH93 | NA | 97% (80–100%) | NA | NA | NA |
 Me10T | 100% (54–100%) | NA | NA | NA | NA |
 Me3TSC | 100% (54–100%) | NA | NA | NA | NA |
 MN3 | 96% (79–99%) | NA | NA | NA | NA |
WHO grade/grade | |||||
 Grade 1/benign | NA | NA | 47% (17–79%) | 88% (78–94%) | NA |
 Grade 2/atypical | NA | NA | 36% (7–81%) | 59% (9–95%) | NA |
 Grade 3/malignant | NA | NA | 50% (18–82%) | 75% (51–89%) | NA |
 Unknown | NA | NA | 90% (68–99%) | 93% (82–97%) | NA |